Acknowledgement for APICES collaboration in BEATcc study published in “The Lancet”

This month, we want to share the acknowledgment that APICES has received in the recent publication of an international clinical trial, titled “Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial”, published in The Lancet in which APICES has collaborated in study setup, coordination and project management, monitoring, data management, medical monitoring, pharmacovigilance, medical writing and statistical analysis.

This means an extra motivation to all APICES team in order to give continuity to the implication we have in every project in which we collaborate. APICES is very proud of the recognition of our work, and we would like to thank GEICO and Dra Ana Oaknin for giving us the opportunity to appear in the acknowledgements of the publication and congratulate them and all the investigators for their project success.

BEATcc trial was designed to establish whether combining atezolizumab with bevacizumab plus chemotherapy improves efficacy in the setting of metastatic, persistent, or recurrent cervical cancer.

You can find more information in the following link: BEATcc study